An Overview of NEB-4: A Promising Drug Target and Biomarker (G4703)

Target Name: NEB

NCBI ID: G4703

An Overview of NEB-4: A Promising Drug Target and Biomarker

New England Journal (NEJ) Variant 4 (NEB-4) is a drug target and a biomarker that has been gaining significant attention in the scientific community due to its unique structure and function. NEB-4 is a small protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. It is a type of transmembrane protein that consists of four extracellular domains and a transmembrane region.

The first domain of NEB-4 is a catalytic domain that contains a heptadecylated cysteine residue, which is known as a 7-transmembrane protein (TM) domain. This domain is responsible for the protein's catalytic activity and plays a key role in its function as a drug target. The second domain is a transmembrane domain that contains a variety of different transmembrane domains, including an ion-exchange domain, a zinc-exchange domain, and a hydrophobic domain.

The third domain of NEB-4 is a carboxy-terminal domain that is rich in acidic amino acids, which is known as a carboxy-terminal region (CTR). This domain is involved in the regulation of the protein's stability and functions as a drug target. The fourth domain of NEB-4 is a C-terminal domain that is rich in amino acids that are involved in the protein's interactions with other proteins, including its interactions with drug molecules.

The unique structure and function of NEB-4 have made it an attractive drug target for researchers. Its catalytic TM domain has been shown to be involved in the regulation of various cellular processes, including cell signaling, and its transmembrane domains have been shown to be involved in the regulation of ion and water transport. Additionally, its CTR domain has been shown to play a key role in the regulation of protein stability and its interactions with other proteins.

Research has also shown that NEB-4 is involved in various physiological processes in the body, including the regulation of pain perception, inflammation, and stress. Its expression has also been shown to be involved in the development and progression of various diseases, including cancer, neurodegenerative diseases, and autoimmune diseases.

Due to its unique structure and function, NEB-4 has been shown to be a promising drug target for a variety of diseases. Studies have shown that inhibiting NEB-4 activity can lead to therapeutic benefits in a variety of conditions, including pain perception, neurodegenerative diseases, and cancer. Additionally, its expression has been shown to be involved in various diseases, including cancer, neurodegenerative diseases, and autoimmune diseases, which makes it an attractive biomarker for these conditions.

In conclusion, NEB-4 is a drug target and biomarker that has gained significant attention due to its unique structure and function. Its catalytic TM domain, transmembrane domains, and CTR domain have been shown to be involved in various cellular processes and physiological functions in the body. Its expression has also been shown to be involved in various diseases, including cancer, neurodegenerative diseases, and autoimmune diseases. Therefore, NEB-4 is a promising drug target and biomarker for a variety of diseases.

Protein Name: Nebulin

Functions: This giant muscle protein may be involved in maintaining the structural integrity of sarcomeres and the membrane system associated with the myofibrils. Binds and stabilize F-actin

More Common Targets